Innovative
Therapeutics for
Better Health

Because Life
Shouldn't Have to
Wait for Migraines

Our Lead Product Candidate

STS101

Dihydroergotamine (DHE) Nasal Powder

Learn More

Clinical Trials

SUMMIT™ Trial

Enrollment Complete

Learn More

Clinical Trials

ASCEND™ Trial

Ongoing

Learn More

Press Releases

Nov 24, 2022

Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Read More

Nov 14, 2022

Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine

Read More